At Zumutor, we are on a mission to develop novel novel immuno onco-therapeutics that drive transformational improvements in cancer treatment through NK cell engagement. We leverage our proven proprietary antibody discovery- INABLR™ for fast track Antibody discovery and development.
Our team works in collaboration with a world class Scientific Advisory Board with expertise in immuno-oncology and clinical development. Our lead asset (ZM008) is a first-in-class antibody that targets certain receptors that blocks NK cell inhibitory signal and enables NK cell activation to generate a potent immune response. Development is on track for an IND filing by Q2 2022 and Phase 1 clinical trial thereafter.
We are headquartered in CIC Cambridge Campus, MA and R&D is carried out at ISO certified lab in Bangalore, India
Company Details
- Employees
- 27
- Founded
- -
- Address
- Zumutor Biologics Inc, Cic Cambridge Campus
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- zumutor.com
- Keywords
- Immuno-oncology, Biologics, Antibody Display.
- HQ
- Cambridge, MA
Zumutor Biologics Questions
Zumutor Biologics's website is zumutor.com
Zumutor Biologics's LinkedIn profile is https://www.linkedin.com/company/zumutor
Zumutor Biologics has
27 employees.
View email and phone details for 27
employees at Zumutor Biologics.
Zumutor Biologics's industry is
Biotechnology Research
Zumutor Biologics's top competitors are
Bugworks Research Inc.,
Oncostem Diagnostics Pvt. Ltd.,
Pandorum Technologies,
Sea6 Energy Pvt Ltd.,
Vyome Therapeutics, Inc.,
Gangagen Biotechnologies,
Eyestem Research,
String Bio Private Limited,
Medgenome,
Farcast Biodynamics.
Zumutor Biologics's categories are Biotechnology Research
Zumutor Biologics's founding year is 2015
